Alkermes plc in $250 Million Direct Registered Sale

Cleary Gottlieb represented Alkermes Public Limited Company in its $250 million direct registered sale of 5,917,160 shares. The deal was structured as a direct registered sale under Alkermes’ shelf registration statement. No underwriter or placement agent was involved in the transaction. Alkermes’ shares are listed on the NASDAQ Global Select Stock Market. The transaction priced on January 10 and closed on January 16.

Alkermes is a global biopharmaceutical company that has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system disorders such as addiction, schizophrenia and depression.